CELL GENESYS INC CEGE (NASDAQd) $ 0.22 Change: -0.03 -13.64% | Volume: 662,327
Sponsored by Click here!

CELL GENESYS - Fundamental Profile

Company Information

Ticker Symbol: CEGE
Exchange: NASD
Contact Info: 500 Forbes Boulevard South San Francisco CA 94080 650 266-3000
CEO/President: Stephen A. Sherwin M.D.
Industry: Medical - Biomedical / Standard Industry Code: 2834
Description: Cell Genesys, Inc. has focused its research and product development efforts on human disease therapies which are based on innovative gene modification technologies. The company\'s strategic objective is to develop and commercialize in vivo and/or ex vivo gene therapies to treat cancer and other major, life-threatening diseases including hemophilia. Cell Genesys\' clinical programs include GVAX cancer vaccines in Phase II studies for prostate cancer and Phase I/II studies for lung cancer.

Share Information

Shares Outstanding: 85,900 (000) Market Value: 21,480 ($000)
Percentage of Inst.Shareholders: 51.92% Number of Inst.Shareholders: 4.78%
Last Quarter Sales: 17.15 ($Mil.) Last Quarter Net Income: -8.41 ($Mil.)
Last Quarter EPS: -0.10 P/E Ratio: 0
Most Recent Earnings: -0.03 on 08/01/08 Earnings Per Share: -0.85
Most Recent Split: Annual Dividend Rate: 0
Most Recent Dividend: Annual Dividend Yield: 0%
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
advertisement